Andra AP fonden Sells 108,937 Shares of DexCom, Inc. $DXCM

Andra AP fonden reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 48.3% during the first quarter, Holdings Channel.com reports. The fund owned 116,663 shares of the medical device company’s stock after selling 108,937 shares during the period. Andra AP fonden’s holdings in DexCom were worth $7,326,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Trust Co. of Vermont raised its holdings in DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after purchasing an additional 145 shares during the last quarter. CVA Family Office LLC lifted its position in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. V Square Quantitative Management LLC boosted its stake in shares of DexCom by 1.8% in the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after purchasing an additional 172 shares during the last quarter. Essex Financial Services Inc. boosted its stake in shares of DexCom by 5.7% in the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after purchasing an additional 175 shares during the last quarter. Finally, IFP Advisors Inc increased its position in shares of DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after buying an additional 178 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on DXCM shares. Raymond James Financial reaffirmed a “strong-buy” rating and set a $91.00 price target on shares of DexCom in a research report on Monday, June 8th. Robert W. Baird set a $80.00 price objective on DexCom in a research report on Friday, May 1st. William Blair raised DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Bank of America dropped their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Canaccord Genuity Group set a $82.00 target price on DexCom and gave the company a “buy” rating in a research report on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.36.

DexCom Stock Down 4.4%

DexCom stock opened at $71.43 on Thursday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The firm has a market capitalization of $27.56 billion, a price-to-earnings ratio of 30.53, a price-to-earnings-growth ratio of 1.23 and a beta of 1.45. The firm’s fifty day moving average price is $72.01 and its two-hundred day moving average price is $68.89. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.32 EPS. On average, equities research analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $72.00, for a total transaction of $1,926,432.00. Following the completion of the sale, the insider owned 355,726 shares of the company’s stock, valued at approximately $25,612,272. This represents a 7.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 71,750 shares of company stock valued at $5,163,241 in the last three months. Insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.